You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
US FDA Clears Neonatal Indication for O3Regional Oximetry
11 June 2019 - - US-based medical technology company Masimo's (NASDAQ: MASI) O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (
Login
Username:

Password:


Related Headlines

Eloxx Pharmaceuticals commences Phase 2b study of exaluren

Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions

US FDA grants orphan drug designation for Lundbeck's asedebart

Renova Pharmaceuticals launches first three US generic products

FDA grants Priority Review to Genentech's Enspryng for MOGAD

CordenPharma increases aseptic fill-finish capacity

Biophytis expands BIO101 obesity study to assess weight regain

THX Pharma secures European patent for Batten-1 in juvenile Batten disease

Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer

Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer

Agilent launches S540MD slide scanner system in US

Cepheid's Xpert Hemorrhagic Fever Panel test granted WHO Emergency Use Listing to support DRC Ebola outbreak response

Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA

AstraZeneca completes global licence agreement for Zegfrovy

AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026